@entity1887 in the medial prefrontal cortex (mPFC) has been associated with the aetiology of negative symptoms and @entity73 of @entity161 , which are both alleviated by @entity1088 and other atypical antipsychotics such as @entity1037 . In rodents, early life exposure to stressful experiences such as social isolation produces a spectrum of symptoms emerging in adult life, which can be restored by antipsychotic drugs. The present series of experiments sought to investigate the effect of @entity1088 (5-10 mg/kg s.c.), @entity1037 (5 mg/kg s.c.), and @entity1767 (0.5 mg/kg s.c.) on @entity935 (DA) and @entity1522 in the prelimbic/infralimbic subregion of the mPFC in group- and isolation-reared @entity35 . @entity35 reared in isolation showed significant and robust deficits in prepulse inhibition of the acoustic startle. In group-reared animals, both @entity1088 and @entity1037 produced a significant increase in DA outflow in the mPFC. Isolation-reared @entity35 showed a significant increase in responsiveness to both atypical antipsychotics compared with group-reared animals. In contrast, the administration of @entity1767 failed to modify dialysate DA levels in mPFC in either group- or isolation-reared animals. The results also show a positive relationship between the potency of the tested antipsychotics to increase the release of DA in the mPFC and their respective affinities for 5-HT1A relative to DA D2 or D3 receptors. Finally, isolation-reared @entity35 showed enhanced neurochemical responses to the highest dose of @entity1088 as indexed by @entity493 , @entity492 , @entity1246 , @entity1160 , @entity2227 , @entity3793 , and @entity669 . The increased DA responsiveness to the atypical antipsychotic drugs @entity1088 and @entity1037 may explain, at least in part, @entity1088 - and @entity1037 -induced reversal of some of the major @entity146 , namely @entity2915 and @entity71 .

Increased responsiveness of @entity935 to atypical, but not typical antipsychotics in the medial prefrontal cortex of XXXX reared in isolation.

@entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine'] @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids'] @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity1246 :: ('MESH:D005680', 'Chemical') :: ['GABA'] @entity1160 :: ('CHEBI:28300', 'Chemical') :: ['glutamine'] @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral components of the social isolation syndrome'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction'] @entity1887 :: ('MESH:D000309', 'Disease') :: ['Dopaminergic hypofunction'] @entity3793 :: ('CHEBI:27570', 'Chemical') :: ['histidine'] @entity71 :: ('MESH:D001289', 'Disease') :: ['attention deficit'] @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyperactivity'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity492 :: ('CHEBI:29995', 'Chemical') :: ['aspartate'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol'] @entity35 :: ('10116', 'Species') :: ['Rats', 'rats'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine'] @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']
@entity35 :: (10116,Species) :: ['rats']
